Gamida Cell Ltd (NASDAQ:GMDA) has been given an average recommendation of “Buy” by the seven brokerages that are covering the company, Marketbeat reports. One investment analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $19.00.
GMDA has been the topic of several recent analyst reports. Oppenheimer set a $18.00 price target on shares of Gamida Cell and gave the company a “buy” rating in a research note on Wednesday. Zacks Investment Research lowered shares of Gamida Cell from a “hold” rating to a “sell” rating in a research note on Thursday, July 4th. Finally, ValuEngine upgraded shares of Gamida Cell from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st.
Institutional investors have recently made changes to their positions in the business. Bank Hapoalim BM acquired a new stake in Gamida Cell in the second quarter valued at $195,000. Edmond DE Rothschild Holding S.A. acquired a new stake in Gamida Cell in the first quarter valued at $53,000. Norges Bank acquired a new stake in Gamida Cell in the fourth quarter valued at $88,000. FMR LLC acquired a new stake in Gamida Cell in the fourth quarter valued at $1,243,000. Finally, Millennium Management LLC acquired a new stake in Gamida Cell in the fourth quarter valued at $210,000. Institutional investors own 1.72% of the company’s stock.
Gamida Cell (NASDAQ:GMDA) last issued its earnings results on Tuesday, May 7th. The company reported ($0.62) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.37) by ($0.25). As a group, equities analysts anticipate that Gamida Cell will post -1.95 EPS for the current fiscal year.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
See Also: Is the QQQ ETF safe?
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.